FPT-SOFTWARE
5.8.2024 09:31:33 CEST | Business Wire | Press release
Global technology company FPT Software, a subsidiary of FPT Corporation, and KITZ Corporation, a world-leading manufacturer of industrial valves and fluid control products, recently signed a strategic partnership agreement. The collaboration leverages FPT Software’s scalable workforce and robust expertise to accelerate the digital transformation initiatives across KITZ’s manufacturing and business operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240804936324/en/
The signing ceremony took place in Tokyo, Japan, with KITZ Corporation CEO Makoto Kohno, FPT Corporation EVP and FPT Software CEO Pham Minh Tuan, and senior executives from both sides. (Photo: Business Wire)
Under the agreement, FPT Software will provide digital solutions to enhance KITZ’s product development and design, global supply chain, maintenance services, and sales and marketing activities. FPT Software will also enhance KITZ’s IT infrastructure through cutting-edge, AI-infused solutions to facilitate its operation and manufacturing with greater precision, efficiency, and safety.
“Driving agility, scalability, and enhanced productivity for our clients has always been FPT Software’s priority. With two decades of experience accompanying industry giants in Japan, a diversified delivery network, and a high-quality workforce globally, we are confident to help KITZ streamline operations and improve time-to-market to stay ahead of the rapidly changing manufacturing landscape,” said Pham Minh Tuan, FPT Corporation Executive Vice President and FPT Software Chief Executive Officer.
"I believe that forming a strategic partnership with FPT, a company that provides the latest technologies and services in the digital field, is a significant step forward. We are currently constructing a factory in Vinh Phuc Province, Vietnam, to manufacture and sell stainless steel valves, which are expected to be in high demand in the future, and a factory to produce high-purity gas valves for the semiconductor equipment market. In Vietnam, which is experiencing remarkable growth, we will continue to provide products and services tailored to our customers' markets and regions by partnering with FPT, a global company that has been at the forefront of DX initiatives for many companies,” said Makoto Kohno, KITZ Corporation Chief Executive Officer.
With nearly 20 years in Japan, FPT Software has become one of the largest foreign technology firms in terms of workforce, with 3,500 employees across 17 local offices and innovation hubs, as well as 15,000 global employees dedicated to the Japanese market. The company has provided services and solutions to over 450 clients worldwide, supporting their digital transformation through strategic consulting services and advanced technological solutions such as AI, machine learning, and cloud computing. The IT firm also plays a significant role in promoting technology cooperation and development between Vietnam and Japan, notably an active member of the Japan Business Federation (Keidanren) and the chair of the Vietnam Association of Digital Transformation in Japan (VADX Japan).
Manufacturing is among FPT Software's key domains. It provides comprehensive strategies and execution processes for digital factories on a global scale, leveraging its deep expertise and wide skills network to deliver complex end-to-end projects that enhance manufacturing operations. These proven competencies and success place FPT Software as a leader and disruptor in manufacturing services by IDC MarketScape and HFS Horizons.
About FPT Software
FPT Software, a subsidiary of FPT Corporation, is a global technology and IT services provider headquartered in Vietnam, with $1 billion in revenue (2023) and over 30,000 employees in 30 countries.
The company champions complex business opportunities and challenges with its world-class services in Advanced Analytics, AI, Digital Platforms, Cloud, Hyperautomation, IoT, Low-code, and so on. It has partnered with over 1,100 clients worldwide, nearly 100 of which are Fortune Global 500 companies in Aviation, Automotive, Banking, Financial Services and Insurance, Healthcare, Logistics, Manufacturing, Utilities, and more. For more information, please visit https://fptsoftware.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240804936324/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom